Enzychem files patent application for COVID-19 drug candidate

By The Science Advisory Board staff writers

April 10, 2020 -- Enzychem Lifesciences has filed a provisional patent application with the U.S. Patent and Trademark Office to cover treating COVID-19 with its compound EC-18.

EC-18 can resolve inflammation by allowing complete viral clearance while minimizing tissue damage, and it may be able to quickly neutralize SARS-CoV-2 by preventing cytokine storm or acute respiratory distress syndrome, according to the company.

Now the company is seeking appropriate partners to develop and commercialize EC-18 worldwide as a potential treatment for COVID-19.

Copyright © 2020 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.